This trial is evaluating whether nivolumab will improve 1 primary outcome and 3 secondary outcomes in patients with Melanoma. Measurement will happen over the course of Approximately 4 weeks.
This trial requires 60 total participants across 3 different treatment groups
This trial involves 3 different treatments. Nivolumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Melanoma is a skin cancer, but it has many signs that may be detected. Common signs include: changes in colour, feeling of itchiness or irritation, mole changing shape, lump changing shape or skin getting ulcerated. Pain with manipulation may occur." - Anonymous Online Contributor
"Melanoma is a relatively rare but aggressive cancer of the skin. It is the major type of skin cancer and a leading cause of cancer related deaths in the United States. The overall 5 year survival rate is about 86% or higher. It usually presents itself as an asymptomatic, pigmented lesion and is found mostly on the trunk. Rarely, the melanoma will spread to the lymph nodes, or to other body organs. As with other types of cancer, it can be detected and managed at any stage because it is not an incurable disease. Prostate cancer is a type of cancer that forms in the prostate gland. It can be very difficult to diagnose because the initial symptoms could be similar to those of prostate cancer." - Anonymous Online Contributor
"The use of topical preparations of topical agents may benefit some patients; however, there is no evidence that it can cure all forms of melanoma." - Anonymous Online Contributor
"Approximately 55,000 new cases are diagnosed each year in the United States. This makes up about 0.7% of the population of the United States. The majority of melanomas diagnosed are acquired nevi. Many of them also develop into melanoma." - Anonymous Online Contributor
"The treatment of melanoma is multidisciplinary and involves surgical resection and nodal staging as well as [immunotherapy](https://www.withpower.com/clinical-trials/immunotherapy) targeting the B(3) natriuretic peptide, anti-CTLA4 antibody, anti-IL-2 receptor, anti-PDL1 antibody and BRAF inhibitor (BORFs of VEGF/IL-6, BORFs of PDGF/CCR2 and others). Radiation therapy for the tumor bed and chemotherapy may be used with a curative intention for a limited proportion of patients." - Anonymous Online Contributor
"UV light causes melanoma. The risk is highest in areas of the sun that are most often in sunlight. People who have a dark skin tone may be more prone to develop melanoma with UV radiation than people with lighter skin. People who wear hats, sunscreens, or long-sleeved shirts are also at increased risk of melanoma. The increased likelihood of melanoma after certain kinds of dermatologic surgery can be reduced by wearing protective sunscreen and a hat, or the use of a new technique called the Ablage operation." - Anonymous Online Contributor
"The survival rate for melanoma is excellent, even in remote rural and remote regional settings. Better survival is seen in Caucasians than in other races. Younger age predicts better survival in melanoma patients." - Anonymous Online Contributor
"Patients with unresectable stage III melanoma should be considered for treatment with Nivolumab. PFS and OS are comparable to those reported for other anti-PD-1/PD-L1 inhibitors. Further studies are needed to determine the most appropriate therapeutic dose and appropriate schedule." - Anonymous Online Contributor
"Melanoma is a highly lethal cancer that is seldom detected until it has metastasised to distant sites. The average time between onset and the diagnosis of melanoma is 5-7 years. The high case fatality rate indicates that melanoma has a high biological aggressiveness. Patients with melanoma can be treated with a wide variety of modalities to control their tumour, including topical medications, surgery, radiation therapy, chemotherapy and, most recently, biological therapies." - Anonymous Online Contributor
"The melanoma research community continues to innovate, and continue to work together to help improve the treatment and outcomes for melanoma. There are still hundreds of clinical samples available for treatment and research studies, and new therapies or treatments are continuing to be explored. As of 2016, an improved survival rate was the only improvement in melanoma treatment. The first line of treatment depends on whether your melanoma has metastasized to the lymph nodes or to other parts of the body as well as the extent of the melanoma. In Stage III melanoma, the only definitive treatment is cutaneous malignant melanoma surgery (CMS), which is surgical removal of most of the tumor and its corresponding skin." - Anonymous Online Contributor
"A broad spectrum of cancers can benefit from the treatment with nivolumab. In a very limited number of patients, even in all cases can make a difference, such as: relapsed or refractory solid tumors, including melanoma. For some patients, particularly women with certain types of breast cancer, nivolumab may be considered as a second-line drug. The use of nivolumab is therefore limited in these cases. But even in these cases, the use of nivolumab is associated with severe and sometimes life-threatening side effects of the drug such as: rash, diarrhea, and thyroid and blood disease." - Anonymous Online Contributor
"It is difficult for nivolumab to be considered a therapeutic substance for the first time due to its low effectiveness, but this is expected to improve. The safety and use of first-line therapy, and the role of other substances should also be reconsidered, as they are still unknown." - Anonymous Online Contributor